Titlebook: Inflammation and Lung Cancer; Steven M. Dubinett Book 2015 Springer Science+Business Media New York 2015 Inflammation.Lung cancer.Micro-RN

HARP

Inflammation and Lung Cancer: Molecular Pathology,nic inflammatory lung diseases and lung cancer. Understanding the molecular pathology of inflammation in the context of the stage of lung tumor development is crucial for developing new anti-inflammatory or immunomodulatory preventive and therapeutic approaches.

灰姑娘

監(jiān)禁

合乎習(xí)俗

Inflammation and Lung Cancer: Eicosanoids, the eicosanoid pathway, or their receptors, make understanding this pathway critical in developing new strategies for the treatment and prevention of lung cancer. New approaches defining the nature of the eicosanoid products produced by different cell types will allow more specific targeting of the

流浪

Book 2015 microenvironment (TME), its?many roles in tumor progression and metastasis, including creation of a hypoxic environment, increased angiogenesis and invasion, changes in expression of micro‐RNAs (miRNAs) and an increase in a stem cell phenotype. The book will also cover the mechanisms of inflammator

江湖郎中

不確定

Inflammation and Lung Cancer: The Relationship to Chronic Obstructive Pulmonary Disease,mmation is one of these factors, with the progression of both diseases substantially modified by the presence of chronic inflammatory cell infiltrates. Here, we review the most likely means by which cigarette smoke-induced inflammation would promote the development of lung cancer in COPD subjects.

苦笑

,Inflammation and Lung Cancer: The Role of Epithelial–Mesenchymal Transition, and recent findings regarding the molecular, cellular, microenvironmental, and environmental factors that drive inflammation-induced EMT-dependent lung carcinogenesis. We also discuss potential approaches for treating or perhaps preventing lung cancer by targeting the inflammation-EMT-cancer axis.

Vulnerary

鄙視讀作

Inflammation and Lung Cancer: Addressing Inflammation with Immunotherapy,e benefit of existing conventional therapies. This chapter reviews immunotherapeutic approaches for lung cancer that have shown promise in early clinical trials and/or have advanced to late-phase development and FDA approval.